{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:27:57Z","timestamp":1787254077220,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04542-y","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:53:22Z","timestamp":1787252002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular pathways and emerging therapeutic strategies in advanced thyroid cancer: from targeted therapy to precision oncology"],"prefix":"10.1007","author":[{"given":"Tanmoy","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhi","family":"Arisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-1884","authenticated-orcid":false,"given":"Hitesh Kumar","family":"Dewangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"3","key":"4542_CR1","first-page":"1","volume":"5","author":"E Farshi","year":"2024","unstructured":"Farshi E. Comprehensive overview of 31 types of cancer: incidence, categories, treatment options, and survival rates. Int J Gastroenterol Hepatol. 2024;5(3):1\u20131.","journal-title":"Int J Gastroenterol Hepatol"},{"key":"4542_CR2","unstructured":"American Cancer Society. Cancer facts and figures 2021. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html, 2021. Accessed Oct 2, 2025."},{"issue":"4","key":"4542_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"issue":"11","key":"4542_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21(11):1142\u20137. https:\/\/doi.org\/10.1158\/1541-7786.MCR-23-0411.","journal-title":"Mol Cancer Res"},{"key":"4542_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23880\/accp-16000102","volume":"1","author":"Are. Sucharitha","year":"2023","unstructured":"Sucharitha Are. An overview of cancer. Adv Cancer Chemother Pharmacol. 2023;1:1\u20138. https:\/\/doi.org\/10.23880\/accp-16000102.","journal-title":"Adv Cancer Chemother Pharmacol"},{"issue":"7","key":"4542_CR6","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/hmg\/9.7.1059","volume":"9","author":"JL Rutkowski","year":"2000","unstructured":"Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet. 2000;9(7):1059\u201366. https:\/\/doi.org\/10.1093\/hmg\/9.7.1059. (PMID: 10767330).","journal-title":"Hum Mol Genet."},{"key":"4542_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/01.mcg.0000159226.63037.a2","volume":"5","author":"BY Choi","year":"2005","unstructured":"Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol. 2005;5:401\u201312. https:\/\/doi.org\/10.1097\/01.mcg.0000159226.63037.a2.","journal-title":"J Clin Gastroenterol."},{"issue":"6","key":"4542_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4161\/cbt.4.6.1818","volume":"4","author":"MV Blagosklonny","year":"2005","unstructured":"Blagosklonny MV. Molecular theory of cancer. Cancer Biol Ther. 2005;4(6):621\u20137. https:\/\/doi.org\/10.4161\/cbt.4.6.1818.","journal-title":"Cancer Biol Ther"},{"key":"4542_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-01-2835","author":"J Rak","year":"2002","unstructured":"Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis\/vascular dependence of tumors? Cancer Res. 2002. https:\/\/doi.org\/10.1158\/0008-5472.CAN-01-2835.","journal-title":"Cancer Res"},{"key":"4542_CR10","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/1078-0432.CCR-16-0384","volume":"22","author":"SA Wells Jr.","year":"2016","unstructured":"Wells SA Jr. Progressin endocrine neoplasia. Clin Cancer Res. 2016;22:4981\u20138.","journal-title":"Clin Cancer Res"},{"key":"4542_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-24029-9","volume":"25","author":"SE Mousavi","year":"2025","unstructured":"Mousavi SE, Jahromi NA, Motlagh Asghari K, et al. Epidemiology of thyroid cancer in Asia in 2020 and its projection to 2040. BMC Public Health. 2025;25:3201.","journal-title":"BMC Public Health"},{"key":"4542_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","volume":"361","author":"SI Sherman","year":"2003","unstructured":"Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501\u201311.","journal-title":"Lancet"},{"key":"4542_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3892\/ol.2025.15266","volume":"30","author":"Z Li","year":"2025","unstructured":"Li Z, Wang N, Li X, Xie Y, Dou Z, Xin H, et al. Thyroid cancer: From molecular insights to therapy. Oncol Lett. 2025;30:520. https:\/\/doi.org\/10.3892\/ol.2025.15266.","journal-title":"Oncol Lett"},{"issue":"3","key":"4542_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4542_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"4542_CR16","doi-asserted-by":"crossref","unstructured":"Kaushal, Y 2025 Rising Trends and Regional Disparities: A Review of Thyroid Cancer Statistics in India","DOI":"10.21203\/rs.3.rs-6667454\/v1"},{"issue":"3","key":"4542_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"A Miranda-Filho","year":"2022","unstructured":"Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(3):168\u201378. https:\/\/doi.org\/10.1016\/S2213-8587(22)00035-3. (PMID: 35271818).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4542_CR18","first-page":"19","volume":"1","author":"M Aleyamma","year":"1956","unstructured":"Aleyamma M. Region-wise pattern of demographic, clinicopathological and treatment profile of thyroid cancers from 96 hospital-based cancer registries in India. ecancer. 1956;1:19.","journal-title":"ecancer."},{"key":"4542_CR19","unstructured":"ICMR-NCDIR 2020 Report of National Cancer Registry Programme. Bengaluru, India ICMR-NCDIR"},{"key":"4542_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"1","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;1:1\u2013133.","journal-title":"Thyroid"},{"issue":"2","key":"4542_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/SLA.0000000000001688","volume":"265","author":"MA Adam","year":"2017","unstructured":"Adam MA, Thomas S, Youngwirth L, Hyslop T, Reed SD, Scheri RP, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265(2):402\u20137.","journal-title":"Ann Surg"},{"key":"4542_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/thy.2021.0539","volume":"4","author":"R Chou","year":"2022","unstructured":"Chou R, Dana T, Haymart M, Leung AM, Tufano RP, Sosa JA, et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid. 2022;4:351\u201367.","journal-title":"Thyroid"},{"issue":"9","key":"4542_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2174\/0113816128322894241004051814","volume":"31","author":"N Sharma","year":"2024","unstructured":"Sharma N, Bhati A, Aggarwal S, Shah K, Dewangan HK. PARP pioneers: using BRCA1\/2 mutation-targeted inhibition to revolutionize breast cancer treatment. Curr Pharm Des. 2024;31(9):663\u201373. https:\/\/doi.org\/10.2174\/0113816128322894241004051814.","journal-title":"Curr Pharm Des"},{"key":"4542_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.11005\/jbm.2019.26.1.51","volume":"1","author":"BH Yoon","year":"2019","unstructured":"Yoon BH, Lee Y, Oh HJ, Kim SH, Lee YK. Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J Bone Metab. 2019;1:51\u201360.","journal-title":"J Bone Metab."},{"key":"4542_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1089\/thy.2021.0033","volume":"9","author":"M Papaleontiou","year":"2021","unstructured":"Papaleontiou M, Chen DW, Banerjee M, Reyes-Gastelum D, Hamilton AS, Ward KC, et al. Thyrotropin suppression for papillary thyroid cancer: a physician survey study. Thyroid. 2021;9:1383\u201390.","journal-title":"Thyroid"},{"issue":"8","key":"4542_CR26","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/ijms21082763","volume":"21","author":"SM Ferrari","year":"2020","unstructured":"Ferrari SM, Fallahi P, Elia G, et al. Systemic therapies for radioiodine-refractory differentiated thyroid cancer. Int J Mol Sci. 2020;21(8):2763.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4542_CR27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.semradonc.2021.03.002","volume":"31","author":"SA Terezakis","year":"2021","unstructured":"Terezakis SA, Lee NY. The role of external beam radiation therapy in thyroid cancer. Semin Radiat Oncol. 2021;31(3):235\u201342.","journal-title":"Semin Radiat Oncol"},{"key":"4542_CR28","first-page":"321","volume":"18","author":"MS Brose","year":"2022","unstructured":"Brose MS, Worden FP, Newbold KL, et al. Systemic treatment of advanced thyroid cancer. Nat Rev Endocrinol. 2022;18:321\u201337.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"4542_CR29","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/ijms21082763","volume":"21","author":"SM Ferrari","year":"2020","unstructured":"Ferrari SM, Fallahi P, Elia G, et al. Targeted therapies in thyroid cancer: new perspectives. Int J Mol Sci. 2020;21(8):2763.","journal-title":"Int J Mol Sci"},{"key":"4542_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.76","author":"E Molinaro","year":"2017","unstructured":"Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from molecular pathogenesis to therapy. Nat Rev Endocrinol. 2017. https:\/\/doi.org\/10.1038\/nrendo.2017.76.","journal-title":"Nat Rev Endocrinol"},{"issue":"10061","key":"4542_CR31","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783\u201395.","journal-title":"Lancet"},{"issue":"7","key":"4542_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41574-020-0346-8","volume":"16","author":"CM Kitahara","year":"2020","unstructured":"Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2020;16(7):341\u201352. https:\/\/doi.org\/10.1038\/s41574-020-0346-8.","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"4542_CR33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"4542_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"issue":"12","key":"4542_CR35","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856\u201383.","journal-title":"Ann Oncol"},{"issue":"1","key":"4542_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","volume":"48","author":"CD Seib","year":"2019","unstructured":"Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):23\u201335.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"4542_CR37","unstructured":"Nikiforov YE, Biddinger PW, Thompson LDR. 2020 Diagnostic pathology and molecular genetics of thyroid tumors. Endocr Pathol"},{"issue":"3","key":"4542_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184\u201399.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"4542_CR39","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States. JAMA. 2017;317(13):1338\u201348.","journal-title":"JAMA"},{"key":"4542_CR40","first-page":"2","volume":"41","author":"M Schlumberger","year":"2020","unstructured":"Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, et al. Follicular thyroid carcinoma. Endocr Rev. 2020;41:2-bnaa004.","journal-title":"Endocr Rev"},{"issue":"1","key":"4542_CR41","first-page":"1","volume":"48","author":"ZW Baloch","year":"2019","unstructured":"Baloch ZW, LiVolsi VA. Pathology of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):1\u201322.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"4542_CR42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610.","journal-title":"Thyroid"},{"issue":"3","key":"4542_CR43","first-page":"R79","volume":"26","author":"C Romei","year":"2019","unstructured":"Romei C, Elisei R. RET mutations in medullary thyroid carcinoma. Endocr Relat Cancer. 2019;26(3):R79\u201399.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"4542_CR44","first-page":"784","volume":"8","author":"R Elisei","year":"2020","unstructured":"Elisei R, Pinchera A, Romei C. Advances in medullary thyroid carcinoma. Lancet Diabetes Endocrinol. 2020;8(9):784\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"4542_CR45","first-page":"555","volume":"38","author":"E Molinaro","year":"2017","unstructured":"Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from diagnosis to therapy. Endocr Rev. 2017;38(6):555\u201386.","journal-title":"Endocr Rev"},{"issue":"1","key":"4542_CR46","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-18-0264","volume":"26","author":"RC Smallridge","year":"2019","unstructured":"Smallridge RC, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2019;26(1):R1\u201317.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"4542_CR47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ, et al. 2021 American thyroid association guidelines for management of anaplastic thyroid cancer. Thyroid. 2021;31(3):337\u201386.","journal-title":"Thyroid"},{"key":"4542_CR48","volume-title":"Williams Textbook of Endocrinology","author":"DS Ross","year":"2020","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. Thyroid physiology and disease mechanisms. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors., et al., Williams Textbook of Endocrinology. 14th ed. Philadelphia: Elsevier; 2020.","edition":"14"},{"issue":"9","key":"4542_CR49","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1172\/JCI60047","volume":"122","author":"GA Brent","year":"2012","unstructured":"Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122(9):3035\u201343.","journal-title":"J Clin Invest"},{"issue":"1","key":"4542_CR50","first-page":"111","volume":"48","author":"SK Grebe","year":"2019","unstructured":"Grebe SK, Hay ID. Thyroid cancer nodal metastasis and lymphatic spread. Endocrinol Metab Clin North Am. 2019;48(1):111\u201328.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"4542_CR51","unstructured":"Sherman, SI 2019 Clinical manifestations and diagnosis of thyroid carcinoma. Endocrinol Metab Clin North Am"},{"issue":"43","key":"4542_CR52","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.2174\/0113816128276948231204111531","volume":"29","author":"H Marwah","year":"2023","unstructured":"Marwah H, Pant J, Yadav J, Shah K, Dewangan HK. Biosensor detection of covid-19 in lung cancer: hedgehog and mucin signaling insights. Curr Pharma Design Curr Pharm Des. 2023;29(43):3442\u201357. https:\/\/doi.org\/10.2174\/0113816128276948231204111531.","journal-title":"Curr Pharma Design Curr Pharm Des"},{"issue":"4","key":"4542_CR53","first-page":"R67","volume":"182","author":"L Fugazzola","year":"2020","unstructured":"Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. European perspective on thyroid cancer diagnosis and management. Eur J Endocrinol. 2020;182(4):R67\u201384.","journal-title":"Eur J Endocrinol"},{"key":"4542_CR54","unstructured":"Ghossein R, Asa SL, Mete O. 2022 Pathologic classification of thyroid carcinoma. In: WHO Classification of Tumours of Endocrine Organs, 5th ed Lyon: IARC"},{"key":"4542_CR55","unstructured":"Haugen BR, 2020 Approach to the patient with advanced thyroid cancer. J Clin Endocrinol Metab"},{"key":"4542_CR56","volume-title":"AJCC cancer staging manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.","edition":"8th ed"},{"issue":"6","key":"4542_CR57","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0102","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"Tuttle RM, Haugen B, Perrier ND. Thyroid cancer staging and risk stratification: AJCC 8th edition update. Thyroid. 2017;27(6):751\u20136.","journal-title":"Thyroid"},{"key":"4542_CR58","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/EJE-19-1023","volume":"182","author":"L Fugazzola","year":"2020","unstructured":"Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. European perspective on thyroid cancer management. Eur J Endocrinol. 2020;182:R67\u201384.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"4542_CR59","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1089\/thy.2012.0043","volume":"22","author":"GW Randolph","year":"2012","unstructured":"Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases in thyroid cancer. Thyroid. 2012;22(11):1144\u201352.","journal-title":"Thyroid"},{"issue":"5","key":"4542_CR60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1210\/er.2017-00236","volume":"39","author":"C Durante","year":"2018","unstructured":"Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. Long-term outcome of differentiated thyroid cancer. Endocr Rev. 2018;39(5):593\u2013620.","journal-title":"Endocr Rev."},{"key":"4542_CR61","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:1054\u201367. https:\/\/doi.org\/10.1056\/NEJMra1501993.","journal-title":"N Engl J Med"},{"key":"4542_CR62","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050.","journal-title":"Cell"},{"key":"4542_CR63","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1530\/ERC-12-0073","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783\u201395. https:\/\/doi.org\/10.1530\/ERC-12-0073.","journal-title":"Lancet"},{"key":"4542_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. BRAF mutation in thyroid cancer. Nat Rev Cancer. 2013;13:184\u201399.","journal-title":"Nat Rev Cancer"},{"key":"4542_CR65","first-page":"676","volume":"159","author":"C Romei","year":"2012","unstructured":"Romei C, Elisei R. RAS mutations in thyroid cancer. Endocr Relat Cancer. 2012;159:676\u201390.","journal-title":"Endocr Relat Cancer"},{"key":"4542_CR66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5999","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, et al. RET alterations and targeted therapy in thyroid cancer. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.78.5999.","journal-title":"J Clin Oncol"},{"key":"4542_CR67","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0400","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M. PI3K\/AKT pathway in thyroid cancer. Endocr Relat Cancer. 2016. https:\/\/doi.org\/10.1530\/ERC-16-0400.","journal-title":"Endocr Relat Cancer"},{"issue":"22","key":"4542_CR68","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2174\/0113816128364722250126172914","volume":"31","author":"RS Chandel","year":"2025","unstructured":"Chandel RS, Dewangan HK. Cancer drug targeting: molecular mechanism, approaches, and regulatory framework. Curr Pharm Des. 2025;31(22):1767\u201380. https:\/\/doi.org\/10.2174\/0113816128364722250126172914.","journal-title":"Curr Pharm Des"},{"key":"4542_CR69","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0204","author":"RC Smallridge","year":"2019","unstructured":"Smallridge RC, et al. Molecular mechanisms of anaplastic thyroid cancer. Endocr Relat Cancer. 2019. https:\/\/doi.org\/10.1530\/ERC-19-0204.","journal-title":"Endocr Relat Cancer"},{"key":"4542_CR70","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0013","author":"V Mancikova","year":"2014","unstructured":"Mancikova V, et al. Epigenetic alterations in thyroid cancer. Endocr Relat Cancer. 2014. https:\/\/doi.org\/10.1530\/ERC-14-0013.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4542_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"issue":"6","key":"4542_CR72","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0129","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"Tuttle RM, et al. Thyroid cancer management guidelines: updates and perspectives. Thyroid. 2017;27(6):751\u20136. https:\/\/doi.org\/10.1089\/thy.2017.0129.","journal-title":"Thyroid"},{"issue":"9941","key":"4542_CR73","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/S0140-6736(14)60403-1","volume":"384","author":"M Schlumberger","year":"2014","unstructured":"Schlumberger M, et al. Strategies of radioiodine ablation in thyroid cancer. Lancet. 2014;384(9941):604\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(14)60403-1.","journal-title":"Lancet"},{"issue":"11","key":"4542_CR74","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/17435889.2025.2501526","volume":"20","author":"H Marwah","year":"2025","unstructured":"Marwah H, Pant J, Shah K, Alam P, Dewangan HK. Anticancer efficacy of dual-loaded SLNs with doxorubicin and pterostilbene: formulation, characterization, and evaluation for breast cancer. Nanomedicine (Lond). 2025;20(11):1249\u201365. https:\/\/doi.org\/10.1080\/17435889.2025.2501526.","journal-title":"Nanomedicine (Lond)"},{"key":"4542_CR75","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206388518251227044948","author":"N Sharma","year":"2026","unstructured":"Sharma N, Bhati A, Shah K, Dewangan HK. Combating sorafenib resistance in hepatocellular carcinoma: unlocking potential with combination therapies and structure-activity relationship studies. Anti-Cancer Agents Med Chem. 2026. https:\/\/doi.org\/10.2174\/0118715206388518251227044948.","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"4542_CR76","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096366956250314043513","author":"H Marwah","year":"2025","unstructured":"Marwah H, Dewangan HK. Synergistic targeting of egfr, esr1, bcl2, and tp53 pathways: a multi-pronged approach for advanced breast cancer therapy. Current cancer drug targets. 2025. https:\/\/doi.org\/10.2174\/0115680096366956250314043513.","journal-title":"Current cancer drug targets"},{"issue":"2","key":"4542_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells SA Jr, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2012;30(2):134\u201341. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4542_CR78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491\u2013501. https:\/\/doi.org\/10.1016\/S2213-8587(21)00120-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"4542_CR79","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in ret-altered thyroid cancers. N Engl J Med. 2020;383(9):825\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2005651.","journal-title":"N Engl J Med"},{"issue":"1","key":"4542_CR80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, et al. Dabrafenib plus trametinib in BRAF V600E\u2013mutated anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7\u201313. https:\/\/doi.org\/10.1200\/JCO.2017.73.6785.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4542_CR81","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, et al. American thyroid association guidelines for management of anaplastic thyroid cancer. Thyroid. 2021;31(3):337\u201386. https:\/\/doi.org\/10.1089\/thy.2020.0944.","journal-title":"Thyroid"},{"issue":"23","key":"4542_CR82","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02788","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, et al. PD-1 blockade in advanced thyroid cancer. J Clin Oncol. 2020;38(23):2620\u20137. https:\/\/doi.org\/10.1200\/JCO.19.02788.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4542_CR83","doi-asserted-by":"publisher","first-page":"607","DOI":"10.18999\/nagjms.87.4.607","volume":"87","author":"R Minamimoto","year":"2025","unstructured":"Minamimoto R, Kato K, Iwano S, Nishii R, Abe Y, Naganawa S. Expanding the therapeutic horizon of 1\u2077\u2077Lu-DOTATATE: a review of current evidence. Nagoya J Med Sci. 2025;87(4):607\u201331. https:\/\/doi.org\/10.18999\/nagjms.87.4.607.","journal-title":"Nagoya J Med Sci"},{"key":"4542_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-026-00290-x","volume":"19","author":"AS Abdlkadir","year":"2026","unstructured":"Abdlkadir AS, Al-Adhami D, Shi H, Sathekge MM, Abu Sheikha A, Mohamad I, et al. Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis. Thyroid Res. 2026;19:7. https:\/\/doi.org\/10.1186\/s13044-026-00290-x.","journal-title":"Thyroid Res"},{"key":"4542_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-025-01996-3","author":"SC Kunte","year":"2025","unstructured":"Kunte SC, et al. Peptide receptor radionuclide therapy with 1\u2077\u2077Lu-DOTATATE and monitoring with somatostatin receptor PET\/CT in patients with advanced differentiated thyroid carcinoma. Mol Imaging Biol. 2025. https:\/\/doi.org\/10.1007\/s11307-025-01996-3.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"4542_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ando.2022.08.001","volume":"84","author":"H Dadgar","year":"2023","unstructured":"Dadgar H, Jafari E, Ahmadzadehfar H, Rekabpour SJ, Ravanbod MR, Kalantarhormozi M, et al. Feasibility and therapeutic potential of the \u2076\u2078Ga\/1\u2077\u2077Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma. Ann Endocrinol (Paris). 2023;84(1):45\u201351. https:\/\/doi.org\/10.1016\/j.ando.2022.08.001.","journal-title":"Ann Endocrinol (Paris)"},{"key":"4542_CR87","doi-asserted-by":"publisher","first-page":"1324587","DOI":"10.3389\/fmed.2024.1324587","volume":"11","author":"C Kratochwil","year":"2024","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenberger R, Morgenstern A. Targeted alpha-particle therapy with actinium-225: current clinical experience and future directions. Front Med (Lausanne). 2024;11:1324587. https:\/\/doi.org\/10.3389\/fmed.2024.1324587.","journal-title":"Front Med (Lausanne)"},{"key":"4542_CR88","doi-asserted-by":"publisher","first-page":"1346210","DOI":"10.3389\/fonc.2024.1346210","volume":"14","author":"M Sathekge","year":"2024","unstructured":"Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. 225Ac-labelled radiopharmaceutical therapy: clinical applications and emerging oncologic indications. Front Oncol. 2024;14:1346210. https:\/\/doi.org\/10.3389\/fonc.2024.1346210.","journal-title":"Front Oncol"},{"issue":"5","key":"4542_CR89","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/cancers16050950","volume":"16","author":"S Poty","year":"2024","unstructured":"Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. Alpha-emitting radionuclides for targeted cancer therapy: advances and clinical translation. Cancers (Basel). 2024;16(5):950. https:\/\/doi.org\/10.3390\/cancers16050950.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4542_CR90","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/pharmaceutics17010074","volume":"17","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Das T, Banerjee S. Targeted alpha-particle therapy with actinium-225 and bismuth-213 radiopharmaceuticals: current progress and therapeutic potential. Pharmaceutics. 2025;17(1):74. https:\/\/doi.org\/10.3390\/pharmaceutics17010074.","journal-title":"Pharmaceutics"},{"key":"4542_CR91","doi-asserted-by":"publisher","first-page":"1365897","DOI":"10.3389\/fendo.2024.1365897","volume":"15","author":"L Fugazzola","year":"2024","unstructured":"Fugazzola L, Colombo C, Persani L. Redifferentiation therapy in radioiodine-refractory differentiated thyroid cancer: current status and future perspectives. Front Endocrinol (Lausanne). 2024;15:1365897. https:\/\/doi.org\/10.3389\/fendo.2024.1365897.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"4542_CR92","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/cancers16081496","volume":"16","author":"FP Worden","year":"2024","unstructured":"Worden FP, Newbold KL, Cabanillas ME. Targeting the MAPK pathway to restore radioiodine uptake in thyroid cancer. Cancers (Basel). 2024;16(8):1496. https:\/\/doi.org\/10.3390\/cancers16081496.","journal-title":"Cancers (Basel)"},{"key":"4542_CR93","doi-asserted-by":"publisher","first-page":"1392104","DOI":"10.3389\/fonc.2025.1392104","volume":"15","author":"LA Dunn","year":"2025","unstructured":"Dunn LA, Sherman EJ, Baxi SS, Tuttle RM, Brose MS. Redifferentiation strategies using BRAF and MEK inhibitors in radioiodine-refractory thyroid cancer. Front Oncol. 2025;15:1392104. https:\/\/doi.org\/10.3389\/fonc.2025.1392104.","journal-title":"Front Oncol"},{"issue":"5","key":"4542_CR94","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/jcm13051243","volume":"13","author":"K Krohn","year":"2024","unstructured":"Krohn K, F\u00fchrer D, Musholt TJ. Molecular targeted therapy and redifferentiation approaches in advanced thyroid cancer. J Clin Med. 2024;13(5):1243. https:\/\/doi.org\/10.3390\/jcm13051243.","journal-title":"J Clin Med"},{"key":"4542_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1372553","volume":"15","author":"M Guo","year":"2024","unstructured":"Guo M, Sun Y, Wei Y, Xu J, Zhang C. Advances in targeted therapy and biomarker research in thyroid cancer. Front Endocrinol. 2024;15:1372553. https:\/\/doi.org\/10.3389\/fendo.2024.1372553.","journal-title":"Front Endocrinol"},{"key":"4542_CR96","doi-asserted-by":"publisher","first-page":"1665545","DOI":"10.3389\/fendo.2025.1665545","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang B, Cen XX, Zhang BR, Zhang W. The effect of BRAF V600E mutation on radioiodine therapy in patients with papillary thyroid carcinoma: A systematic review and meta-analysis. Front Endocrinol. 2025;16:1665545. https:\/\/doi.org\/10.3389\/fendo.2025.1665545.","journal-title":"Front Endocrinol"},{"key":"4542_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02260-x","volume":"41","author":"JK Tan","year":"2024","unstructured":"Tan JK, Awuah WA, Roy S, et al. Exploring the advances of single-cell RNA sequencing in thyroid cancer: a narrative review. Med Oncol. 2024;41:27. https:\/\/doi.org\/10.1007\/s12032-023-02260-x.","journal-title":"Med Oncol"},{"key":"4542_CR98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13044-025-00223-0","volume":"18","author":"D Sun","year":"2025","unstructured":"Sun D, Zhang X, Jin X, et al. BRAF V600E mutation is associated with prognosis in radioactive iodine-refractory thyroid cancer: A retrospective analysis of clinical trials. Thyroid Res. 2025;18:5. https:\/\/doi.org\/10.1186\/s13044-025-00223-0.","journal-title":"Thyroid Res"},{"issue":"10","key":"4542_CR99","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1089\/thy.2023.0700","volume":"34","author":"SS Wen","year":"2024","unstructured":"Wen SS, Wu YJ, Wang JY, et al. BRAF V600E\/p-ERK signaling promotes tumor progression in papillary thyroid cancer. Thyroid. 2024;34(10):1246\u201359. https:\/\/doi.org\/10.1089\/thy.2023.0700.","journal-title":"Thyroid"},{"issue":"4","key":"4542_CR100","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/pharmaceutics16040515","volume":"16","author":"MH Al-Qahtani","year":"2024","unstructured":"Al-Qahtani MH, Alharbi KS, Almalki WH. Nanotechnology-based drug delivery systems for thyroid cancer therapy: current advances and future perspectives. Pharmaceutics. 2024;16(4):515. https:\/\/doi.org\/10.3390\/pharmaceutics16040515.","journal-title":"Pharmaceutics"},{"key":"4542_CR101","doi-asserted-by":"publisher","first-page":"1342186","DOI":"10.3389\/fphar.2024.1342186","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang X, Chen H, et al. Lipid nanoparticle-mediated RNA delivery for cancer therapy: recent progress and applications. Front Pharmacol. 2024;15:1342186. https:\/\/doi.org\/10.3389\/fphar.2024.1342186.","journal-title":"Front Pharmacol"},{"issue":"7","key":"4542_CR102","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.3390\/ijms25073821","volume":"25","author":"M Rahman","year":"2024","unstructured":"Rahman M, Islam R, Hossain S, et al. Polymeric nanoparticles for targeted drug delivery in cancer therapy: advances and challenges. Int J Mol Sci. 2024;25(7):3821. https:\/\/doi.org\/10.3390\/ijms25073821.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4542_CR103","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/cancers16050933","volume":"16","author":"L Zhou","year":"2024","unstructured":"Dewangan, H.K., Sharma, R., Shah, K. et al. Development of FA-conjugated PAMAM dendrimer as potential antioxidant therapy for cancer cells. J. Mater. Res. 2025; 40: 1405\u20131416. https:\/\/doi.org\/10.1557\/s43578-025-01587-7","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4542_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2023.104967","volume":"17","author":"I Khan","year":"2024","unstructured":"Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities in cancer therapy. Arabian J Chem. 2024;17(2):104967. https:\/\/doi.org\/10.1016\/j.arabjc.2023.104967.","journal-title":"Arabian J Chem"},{"key":"4542_CR105","doi-asserted-by":"publisher","first-page":"1339750","DOI":"10.3389\/fbioe.2024.1339750","volume":"12","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, He C, Riviere JE, Monteiro-Riviere NA, Lin Z. Lipid nanoparticles and targeted nanocarriers for RNA-based therapeutics in cancer. Front Bioeng Biotechnol. 2024;12:1339750. https:\/\/doi.org\/10.3389\/fbioe.2024.1339750.","journal-title":"Front Bioeng Biotechnol"},{"key":"4542_CR106","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128384257251211183939","author":"R GuptaRajni","year":"2026","unstructured":"Rajni, Shah K, Dewangan HK. Nanovaccines in Cancer Immunotherapy: Lymph Node-Targeted Strategies and Mechanistic Insights. Curr Pharm Des. 2026. https:\/\/doi.org\/10.2174\/0113816128384257251211183939.","journal-title":"Curr Pharm Des"},{"issue":"11","key":"4542_CR107","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor MH, Lee CH, Makker V, et al. Phase Ib\/II trial of lenvatinib plus pembrolizumab in patients with advanced solid tumors including thyroid cancer. J Clin Oncol. 2020;38(11):1154\u201363. https:\/\/doi.org\/10.1200\/JCO.19.01598.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4542_CR108","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Hu MI, Wirth LJ, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutated anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7\u201313. https:\/\/doi.org\/10.1200\/JCO.2017.73.6785.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4542_CR109","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1078-0432.CCR-18-1304","volume":"25","author":"LA Dunn","year":"2019","unstructured":"Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib redifferentiation of BRAF-mutant, RAI-refractory thyroid cancers. Clin Cancer Res. 2019;25(2):654\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1304.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"4542_CR110","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1158\/1078-0432.CCR-15-1345","volume":"21","author":"SM Rothenberg","year":"2015","unstructured":"Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF-mutant metastatic papillary thyroid cancer with dabrafenib-trametinib combination therapy. Clin Cancer Res. 2015;21(23):5640\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1345.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04542-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:53:32Z","timestamp":1787252012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04542-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":110,"alternative-id":["4542"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04542-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors depict no conflict of interest that could have appeared to influence the work reported.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No generative AI assistance was used during review writing.","order":3,"name":"Ethics","label":"Declaration of generative AI","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Grammarly- for spell check, better writing.Mendeley- for reference and citation assistance.","order":4,"name":"Ethics","label":"Declaration of software assistance","group":{"name":"EthicsHeading","label":"Declarations"}}]}}